BiotechTube

KHK7580 + KRN1493

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism

Trial Timeline

Sep 1, 2015 → Nov 1, 2016

NCT ID
NCT02549391

About KHK7580 + KRN1493

KHK7580 + KRN1493 is a phase 2/3 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02549391. Target conditions include Secondary Hyperparathyroidism.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT02549391Phase 2/3Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
dirucotide + PlaceboEli LillyPhase 2/3
65
dirucotideEli LillyPhase 2/3
65
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Birabresib Dose 20 mgMerckPhase 1
33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
77
RanibizumabNovartisApproved
85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
77

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85